We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Paper-Based Test Monitors Liver Damage

By LabMedica International staff writers
Posted on 11 Oct 2012
A postage stamp-sized, paper-based device could provide a simple and reliable way to monitor for liver damage.

The paper-based microfluidic device is inexpensive and can be employed at the point of contact to test aspartate aminotransferase (AST) and alanine aminotransferase (ALT) levels concurrently, giving doctors near real time feedback and thus allowing them to make treatment plans, if necessary, on the spot. More...


Scientists at the Beth Israel Deaconess Medical Center (BIDMC; Boston, MA, USA) constructed the device using layers of patterned paper and a plasma separation membrane. A hole in the lamination allows for a finger stick or pipetted drop of whole blood or serum to be applied to the plasma separation membrane. The blood then wicks into the layers of paper, and through the microfluidic channels travels to separate zones for testing AST and ALT.

Jason Rolland, PhD, Senior Director of Research at Diagnostics for All (DFA; Cambridge, MA, USA) said, “A drop of blood is applied to the device and the activity of the enzymes present in the blood sample leads to changes in levels of specific dyes present in the paper zones. This gives rise to color changes that can be compared against a visual read guide and correspond to a concentration range for each of the enzymes." The test takes about 15 minutes to perform. The color changes, for example, from shades of blue to shades of pink, when increasing levels of AST are detected in the blood. In rigorous clinical tests using 223 whole blood and serum specimens from the paper-based test performed at greater than 90% accuracy compared against the gold standard automated platform test.


Additionally, the device could be used as a "triage test" in developed or developing nations to quickly and inexpensively rule out the need for automated laboratory testing. For example, if blood tested with the device shows that the liver enzymes fall below a certain threshold, more expensive testing could be avoided, saving healthcare costs and clinical resources. Nira Pollock, MD, PhD, the co-lead author said, “The next stage for the device is to test it in the field. We are working for a preliminary field study of the paper-based test in Ho Chi Minh City, Vietnam.” The study was published on September 19, 2012, in the journal Science Translational Medicine.

Related Links:
Beth Israel Deaconess Medical Center
Diagnostics For All


Platinum Member
Xylazine Immunoassay Test
Xylazine ELISA
Verification Panels for Assay Development & QC
Seroconversion Panels
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
Spinal Fluid Cell Count Control
Spinalscopics
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.